Immunotherapy duo shows promise for rare, Tough-to-Treat ovarian cancer
NCT ID NCT03355976
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This study tests whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better than nivolumab alone for people with advanced clear cell ovarian, fallopian tube, or peritoneal cancer. About 46 participants will receive either one or both drugs to see if tumors shrink. The goal is to find a more effective treatment for this aggressive cancer type.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
The Miriam Hospital
Providence, Rhode Island, 02906, United States
-
University of Illinois Chicago
Chicago, Illinois, 60612, United States
-
Women & Infants Hospital
Providence, Rhode Island, 02905, United States
Conditions
Explore the condition pages connected to this study.